1. Home
  2. BLNK vs ADCT Comparison

BLNK vs ADCT Comparison

Compare BLNK & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blink Charging Co.

BLNK

Blink Charging Co.

HOLD

Current Price

$0.78

Market Cap

89.3M

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$4.28

Market Cap

496.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLNK
ADCT
Founded
2009
2011
Country
United States
Switzerland
Employees
594
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
89.3M
496.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BLNK
ADCT
Price
$0.78
$4.28
Analyst Decision
Buy
Strong Buy
Analyst Count
7
6
Target Price
$2.13
$7.60
AVG Volume (30 Days)
5.7M
1.6M
Earning Date
11-06-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$106,631,000.00
$75,209,000.00
Revenue This Year
N/A
$10.36
Revenue Next Year
$17.87
$3.87
P/E Ratio
N/A
N/A
Revenue Growth
N/A
6.35
52 Week Low
$0.63
$1.05
52 Week High
$2.65
$4.80

Technical Indicators

Market Signals
Indicator
BLNK
ADCT
Relative Strength Index (RSI) 24.13 55.06
Support Level $1.24 $3.15
Resistance Level $1.43 $4.62
Average True Range (ATR) 0.09 0.40
MACD -0.04 0.01
Stochastic Oscillator 0.88 77.98

Price Performance

Historical Comparison
BLNK
ADCT

About BLNK Blink Charging Co.

Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: